EIKN Stock Chart & Stats
$11.39
--
Market closed
$11.39
--
Day’s Range― - ―
52-Week Range$7.90 - $17.40
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
$616.94M
Enterprise Value$427.28
Total Cash (Recent Filing)$531.58M
Total Debt (Recent Filing)$252.22M
Price to Earnings (P/E)―
Beta1.85
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding54,165,030
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)-0.92
Price to Sales (P/S)0.00
P/FCF Ratio-3.45
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$31.00Price Target Upside172.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Eikon Therapeutics, Inc. News
EIKN FAQ
What was Eikon Therapeutics, Inc.’s price range in the past 12 months?
Eikon Therapeutics, Inc. lowest stock price was $7.90 and its highest was $17.40 in the past 12 months.
What is Eikon Therapeutics, Inc.’s market cap?
Eikon Therapeutics, Inc.’s market cap is $616.94M.
When is Eikon Therapeutics, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Eikon Therapeutics, Inc.’s earnings last quarter?
Currently, no data Available
Is Eikon Therapeutics, Inc. overvalued?
According to Wall Street analysts Eikon Therapeutics, Inc.’s price is currently Undervalued.
Does Eikon Therapeutics, Inc. pay dividends?
Eikon Therapeutics, Inc. does not currently pay dividends.
What is Eikon Therapeutics, Inc.’s EPS estimate?
Eikon Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Eikon Therapeutics, Inc. have?
Eikon Therapeutics, Inc. has 54,165,030 shares outstanding.
What happened to Eikon Therapeutics, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Eikon Therapeutics, Inc.?
Currently, no hedge funds are holding shares in EIKN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Eikon Therapeutics, Inc. Stock Smart Score
Company Description
Eikon Therapeutics, Inc.
Eikon Therapeutics, Inc. is a clinical biopharmaceutical company, established in 2019 and headquartered in Millbrae, California, operating within the United States. The company is dedicated to developing groundbreaking medicines to address significant unmet medical needs. It utilizes a proprietary platform capable of precisely characterizing protein interactions inside living cells. Eikon's drug pipeline includes EIK1001, a systemically delivered TLR 7/8 dual-agonist designed to activate both innate and adaptive anti-cancer immune responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors for ovarian, breast, prostate, and pancreatic cancers. Notably, EIK1004 is brain-penetrant, offering a therapeutic approach for brain metastases and primary brain malignancies. Additionally, EIK1005 is a potent WRN helicase inhibitor and anti-tumor agent aimed at MSI-high tumors, alongside EIK1006.
EIKN Stock 12 Month Forecast
Average Price Target
$31.00
▲(172.17% Upside)
C4 Therapeutics
―
Foghorn Therapeutics
―
Ginkgo Bioworks Holdings
―
Immuneering
―
Prime Medicine, Inc.
―
Ownership Overview
22.31% Insiders
1.42% Mutual Funds
20.21% Other Institutional Investors
52.04% Public Companies and
Individual Investors